Page 1927 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

1354 Index

Rhinocerebral mucomycosis, 686 ScvO , 244, 244t microbiological causes, 563
2
Rib fractures, 1160 Seasonal influenza, 716 related epidemiological phenomena of,
Richmond Agitation-Sedation Scale (RASS), Secondary bacterial peritonitis, 1080–1082, 563–564
148, 148t, 759 1081t, 1082f sources of, 563
Ricin toxin, 751 Secondary data use for practice monitoring extravascular lung water, 569
Rickettsial diseases, 718–719 and research, 54, 54f fluid therapy for, 570–572, 571t
Rocky Mountain spotted fever as, Secular trends research concepts relevant to glycemic control, 575
718–719 quality measurement and, 9t, 10 hemodynamic management of, 572–573
Rifabutin, 641 Sedation immunoparalysis and, 551–556
RIFLE classification assessing adequacy of, 148, 148t apoptosis, 555
of acute kidney injury, 916, 916f drugs for, of mechanically ventilated appropriate diagnostic tools and
https://kat.cr/user/tahir99/
modification of, 916–917 patients, 149–153, 150f, 151t, 152t monitoring, 555–556
Rift Valley fever, 718, 741 indications for, 145–146 clinical evidence and relevance of
Right atrial pressure, 263 sleep and, 160–161, 160t immunosuppression, 554
Right heart dysfunction, 309 spinal injuries and, 1151 definition of systemic sepsis-
Right heart syndromes Sedation Agitation Scale (SAS), 148 induced, 553
pathophysiology of, 309–312, 309f, 310t, Sedatives, 112–113 evolution to immunoparalysis,
311f, 312ft administering, in intensive-care unit, 553, 553f
recognizing, 310–312, 310t 148–149 future therapeutic approaches, 556
Right ventricle afterload, reducing, Seizures history—definition, 551
316–317 in intensive care unit, 779–786 measurement of cell surface markers,
Right ventricle dilation, 312–313 classification of, 780–781 554–555
Right ventricle ischemia, reducing, clinical manifestations, 781–782 measurement of circulating
316–317 diagnostic approach, 782–783 mediators, 554
Right ventricular dysfunction, mechanisms epidemiology and outcome, modification of, 554–556
and management of, 275–276 779–780, 779t natural history of infection and sepsis
Right ventricular failure, 258, 1103 management approach, 783–786, syndrome, 551–552
diagnosis and management of, 258–259 783t, 785t Interleukin-6 (IL-6), 567
Right ventricular infarction, 198–199, 306, pathogenesis and pathophysiology, 781 laboratory studies and radiologic
312–313 international League Against Epilepsy’s imaging, 567
Right ventricular overload, infarction and, (ILAE) classification of, 780 mobility, 575
236t, 237–238 Selected dermatoses monitoring, hemodynamic and
Right ventricular physiology, 309 miliaria, 1304, 1304f cardiopulmonary monitoring
Riker Sedation-Agitation Scale, 759 pressure ulcers, 1304 in, 569
Risk-adjusted CUSUM charts, 13 Selective serotonin reuptake inhibitors, mortality probability model 0 at zero
Risk-adjusted p charts, 13 1221–1222, 1221t hours, 569
Risk ratio, 46 Self-contained underwater breathing new directions, 575–576
Risperidone, 153 apparatus (SCUBA), 1319 nutrition and metabolism, 574
Rituximab, 604 Selye, Hans, 980 organ dysfunction in, 565–566
Robustness, sensitivity analysis and, Sensitivity analysis, 40, 42 pathophysiology, 564–565, 564f
42–43, 43f robustness and, 42–43, 43f microbiology, 564–565
Rocky Mountain spotted fever, 676, Sensitivity of test, 47 patient presentation and diagnostic
718–719, 1299 Sentinel bleed, postoperative hemorrhage approach, 566–567
Rocuronium, 154 and, 1067 procalcitonin, 567–568, 568t
Rubella virus, 673 Seoul virus, 742 recombinant human activated
Rumack-Matthew nomogram, Sepsis, 263, 562–576 protein C, 574
1207, 1207f, 1208 abdomen as occult source of, 1083, 1083ft renal replacement therapy, 574–575
acute liver failure and, 1024 sequential organ failure assessment,
S acute physiology and chronic health 568–569
Saaremaa virus, 742 evaluation, 568 sickle cell disease and, 911
SAFE clinical trial, 572 antibiotic therapy for, 569–570 simplified acute physiology score, 568
Safety biliary tract, 1080 soluble triggering receptor expressed on
question of, 32 biomarkers of, 567 myeloid cells, 567
science of, 32–33, 33t brain injury associated with, 113 source control for, 570
Safety infrastructure, investing in, 34 bundles, 573–574, 574t sources of, 563
Safety scorecard, 36–37 in burn patients, 1187 systemic inflammatory response syndrome
St. Louis encephalitis, 672 cardiac output and fluid (SIRS) and, 107
Salicylates, 1220–1221, 1220t, 1221t responsiveness, 569 venous oxygen saturation, 569
Salvage therapy, for endoscopically as cause of pulmonary hypertension, 313 venous thromboembolism and stress ulcer
uncontrolled bleeding, central venous pressure, 569 prophylaxis, 575
1009–1010 cirrhosis and, 1030 Sepsis bundles, 573–574, 574t
SAPS II scoring system, 85, 89, 568 corticosteroids, 573 Septic encephalopathy, 818–819
Sarcopenia of aging, 108 C-reactive protein, 567 Septic intracranial thrombophlebitis, 686–687
SARS, 57, 720 definitions and epidemiology, Septic myocardial dysfunction, 272
Scleroderma, 1243–1244 562–564, 563ft Septic myocardium, 236

Index.indd 1354 23-01-2015 15:33:53